PMID- 24390661
OWN - NLM
STAT- MEDLINE
DCOM- 20140609
LR  - 20211021
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 35
IP  - 4
DP  - 2014 Apr
TI  - S-1-based therapy versus S-1 monotherapy in advanced gastric cancer: a 
      meta-analysis.
PG  - 3283-93
LID - 10.1007/s13277-013-1429-0 [doi]
AB  - This study aimed to derive a more precise estimate of the prognostic significance 
      of S-1-based therapy over S-1 monotherapy in patients with advanced gastric 
      cancer (AGC), including overall survival (OS) time, progression-free survival 
      (PFS) time, objective response rate (ORR), and adverse events (AEs). Studies 
      stratifying OS, PFS, ORR, and AEs in AGC patients in an S-1-based therapy versus 
      an S-1 monotherapy setting were eligible for analysis by systematic computerized 
      PubMed, Embase and Cochrane Library searches. Data from these studies were pooled 
      using STATA package version 11.0. Six studies that investigated outcomes in a 
      total of 913 AGC cases, of which 443 (48.5%) received S-1-based therapy and 470 
      (51.5%) received S-1 monotherapy, were included in the meta-analysis. Median OS 
      and median PFS were significantly prolonged in AGC patients receiving S-1-based 
      therapy compared with those receiving S-1 monotherapy (hazard ratio [HR] 0.83, 
      95% confidence interval [CI] 0.71-0.96, P = 0.015, and HR 0.69, 95% CI 0.60-0.80, 
      P = 0.000, respectively). The ORR favored patients with S-1-based therapy (OR 
      1.65, 95% CI 1.34-2.06, P = 0.000). Higher incidence of grade 3/4 neutropenia was 
      found in patients with S-1-based therapy (P = 0.000). For the Asian population, 
      S-1-based therapy significantly improved OS and PFS and enhanced ORR in 
      comparison to S-1 monotherapy. The safety profile was poorer in patients with 
      S-1-based therapy, but could be considerable between the S-1-based therapy and 
      S-1 monotherapy group. Our conclusion needs to be confirmed via high-quality 
      trials and the results need to be reproduced in other regions and populations.
FAU - Wu, Jun-Rong
AU  - Wu JR
AD  - Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical 
      University, Nanning, 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Tang, Wei-Zhong
AU  - Tang WZ
FAU - Chen, Xi
AU  - Chen X
FAU - Xie, Yan-Tong
AU  - Xie YT
FAU - Chen, Si-Yuan
AU  - Chen SY
FAU - Peng, Qi-Liu
AU  - Peng QL
FAU - Xie, Li
AU  - Xie L
FAU - Deng, Yan
AU  - Deng Y
FAU - Li, Tai-jie
AU  - Li TJ
FAU - He, Yu
AU  - He Y
FAU - Wang, Jian
AU  - Wang J
FAU - Li, Shan
AU  - Li S
FAU - Qin, Xue
AU  - Qin X
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20140105
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
RN  - 0 (Drug Combinations)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 5VT6420TIG (Oxonic Acid)
SB  - IM
CIN - Tumour Biol. 2014 Aug;35(8):7405. PMID: 24943682
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Disease-Free Survival
MH  - Drug Combinations
MH  - Humans
MH  - Oxonic Acid/adverse effects/*therapeutic use
MH  - Stomach Neoplasms/*drug therapy/mortality
MH  - Tegafur/adverse effects/*therapeutic use
EDAT- 2014/01/07 06:00
MHDA- 2014/06/10 06:00
CRDT- 2014/01/07 06:00
PHST- 2013/09/05 00:00 [received]
PHST- 2013/11/13 00:00 [accepted]
PHST- 2014/01/07 06:00 [entrez]
PHST- 2014/01/07 06:00 [pubmed]
PHST- 2014/06/10 06:00 [medline]
AID - 10.1007/s13277-013-1429-0 [doi]
PST - ppublish
SO  - Tumour Biol. 2014 Apr;35(4):3283-93. doi: 10.1007/s13277-013-1429-0. Epub 2014 
      Jan 5.